Singulair (montelukast), the second leukotriene receptor antagonist for asthma
September 1998
You'll hear more about Singulair (montelukast), the second leukotriene receptor antagonist for asthma. Is now approved in both the U.S. and Canada.
It's similar to Accolate (zafirlukast).
Both Accolate and Singulair block the effects of leukotrienes in the lungs...leading to a reduction in bronchoconstriction, mucous secretion and inflammation.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive